Hyperfractioned Regional Nodal Irradiation for women with invasive breast cancer

Trial ID:

IRB-22-7881

Ray Lin, M.D.

This study will test the safety and effectiveness of regional-nodal irradiation given over 3 weeks compared to the standard of 5 weeks.

Inclusion Criteria

*Be 18 years or older
*Have pathologically confirmed invasive breast cancer
*Prior mastectomy or lumpectomy with axillary evaluation

Contact Info:

• Clinical Research Services
• CRSLeadership@scrippshealth.org